Ask about this productRelated genes to: PON1 antibody
- Gene:
- PON1 NIH gene
- Name:
- paraoxonase 1
- Previous symbol:
- PON
- Synonyms:
- ESA
- Chromosome:
- 7q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2014-11-19
Related products to: PON1 antibody
Related articles to: PON1 antibody
- Human carboxylesterase 1 (hCE1) is highly expressed in the liver and can be released into the bloodstream upon hepatocellular injury, suggesting its potential as a biomarker for liver damage. However, current methods for measuring hCE1 activity suffer from poor selectivity and insufficient sensitivity and are easily interfered with by serum albumin (HSA), butyrocholinesterase (BChE), and paraoxonase 1 (PON1). In this study, a novel fluorescent probe, NCMNe, was designed and synthesized, and an ultrasensitive liquid chromatography-fluorescence detection (LC-FD) method was established for quantifying plasma hCE1 activity and evaluating its feasibility as a biomarker of liver injury. Specificity studies showed that NCMNe was selectively hydrolyzed by hCE1 without interference from HSA, PON1, or BChE. The developed LC-FD method achieved a lower limit of quantification of 0.0001 μM, representing the most sensitive method reported to date for hCE1 activity determination. Clinical sample analysis revealed that plasma hCE1 activity in patients with hepatitis B was significantly higher than that in healthy controls and was strongly correlated with aspartate transaminase (AST)and alanine transaminase (ALT). Receiver operating characteristic (ROC) curve analysis demonstrated that plasma hCE1 activity measurement was effective for detecting liver pathology (AUC = 0.901, p < 0.0001), with diagnostic performance comparable to that of ALT and AST. Collectively, the proposed LC-FD method enables highly sensitive and selective determination of plasma hCE1 activity and supports hCE1 as a promising serum biomarker for liver injury, providing a new approach for early diagnosis and disease assessment. - Source: PubMed
Publication date: 2026/08/29
Zhao XuanWang Qian-QianZhang Qi-ChenXu XinWang Dan-Dan - Hepatocellular carcinoma (HCC) is driven by extensive metabolic reprogramming, vascular remodeling, and immune microenvironmental dysfunction. Although numerous stratification signatures have been proposed, few are grounded in clinically derived serum multi-omics and biologically linked to endothelial remodeling, endothelial regulation, and immune exclusion. - Source: PubMed
Publication date: 2026/08/31
Yang LuxiJin QiaoyingChen LuLiu YatingLi Yumin - Enzyme paraoxonase 1 () plays a protective role against atherosclerosis by preventing the oxidation of low-density lipoproteins (LDL). Polymorphisms in the , particularly Q192R and L55M, have been shown to affect the enzyme activity and, consequently, the cardiovascular risk. The present study aimed to evaluate the association between haplotypes comprising the Q192R and L55M polymorphisms and the severity of coronary atherosclerosis in a Polish population. The retrospective study involved 282 individuals of both sexes, divided into two groups following coronarography. The study group included patients after PCI (percutaneous coronary intervention) with stent implantation or patients who qualified for CABG (coronary artery bypass graft), with stenoses of minimum 70% ( = 140), whereas the control group included those after coronarography and without essential lesions in coronary vessels ( = 142). The Q192R polymorphism was identified by PCR-RFLP. The haplotypes 192R-55L and 192R-55M have been shown to be statistically significantly associated with a higher risk of atherosclerosis that requires PCI/CABG (OR = 2.06, 95% CI: 1.29-3.28, = 0.0022; OR = 1.77, 95% CI: 1.17-2.69, = 0.007; respectively). Furthermore, the risk of atherosclerosis requiring PCI or CABG was 53% lower in patients with the 192Q-55L haplotype (OR = 0.47, 95% CI: 0.34-0.66, = 0.000013). Haplotypes 192R-55L and 192R-55M may increase the risk of atherosclerosis requiring PCI/CABG, whereas the 192Q-55L haplotype may lower the risk. - Source: PubMed
Publication date: 2026/08/14
Rychlik-Sych MariolaBarańska MałgorzataDudarewicz MichałOwczarek Jacek - High-density lipoprotein (HDL)-associated paraoxonase-1 (PON1) contributes substantially to the antioxidant and anti-inflammatory functions of HDL. Impairment of these protective properties has been associated with Alzheimer's disease (AD) and other forms of dementia, particularly those involving neurovascular dysregulation. In the present study, we investigated for the first time the potential involvement of the putative physiological lactonase activity of PON1 in serum samples from a large cohort of older adults (n = 691), including cognitively healthy controls and patients with mild cognitive impairment (MCI), AD, vascular dementia (VAD), mixed AD/VAD (MIXED dementia), and other forms of dementia. A difference was observed between controls and MCI patients (-34%, < 0.001). The next largest differences were observed in the VAD and MIXED dementia groups, both showing a decrease of approximately 25% compared with controls ( < 0.05 and < 0.001, respectively), and in AD patients (-14%, < 0.05). After adjustment for confounding factors, only MCI and MIXED dementia remained significantly different from controls. These findings suggest that reduced serum PON1 lactonase activity is already detectable at the MCI stage and is particularly evident in conditions combining neurodegenerative and vascular pathology. Longitudinal studies are required to determine whether lower PON1 lactonase activity precedes, accompanies, or follows cognitive decline. - Source: PubMed
Publication date: 2026/08/13
Riccetti RaffaellaTrentini AlessandroMola GianmarcoBrombo Gloriadi Paola Dario FrancescoCastellazzi MassimilianoCandeloro RaffaellaManfrinato Maria CristinaZuliani GiovanniCervellati Carlo - : Clinical outcomes after traumatic brain injury (TBI) remain difficult to predict, highlighting the need for more sensitive diagnostic and prognostic biomarkers, particularly in polytrauma. This study aimed to identify TBI-specific proteomic signatures in plasma and extracellular vesicles (EV)-enriched fractions of critically injured trauma patients. : Seventy-five severely injured adult trauma patients (ISS ≥ 16) were included: isolated severe TBI (TBI; AIS ≥ 4, other AIS ≤ 1, = 23), polytrauma with TBI (PT-TBI; AIS ≥ 4, = 22), and polytrauma without TBI (PT; AIS = 0, = 30). 24 age- and sex-matched healthy volunteers served as controls. Neat plasma and EV-enriched fractions were profiled using HPLC-MS/MS. Differentially expressed proteins (DEP) were analyzed bioinformatically, and associations with clinical parameters were assessed using Spearman's correlation. : The EV-enriched plasma fraction yielded more DEPs than neat plasma (846 vs. 258). Most DEPs were linked to polytrauma, with plasma reflecting metabolism and EVs showing translation and protein catabolism signatures. Among TBI-context proteins, EV-associated NRCAM and AQR and plasma IGHV1-69D, MASP1, PON1, and IGFBP7 remained significantly associated with TBI after adjustment for confounder. Notably, only EV-associated proteins correlated with injury-related clinical parameters. AQR negatively correlated with GCS ( = -0.51, < 0.0001), while elevated NRCAM, AQR, and plasma MASP1 were associated with neurological deterioration and neurosurgical intervention. : EV-enriched plasma proteomics enhances biomarker discovery in polytrauma, revealing distinct pathways and greater sensitivity than whole plasma. While most changes reflect systemic injury, EV-associated NRCAM and AQR, along with plasma MASP1, show TBI-specific associations with neurological status, highlighting their potential as candidate TBI biomarkers for further study. - Source: PubMed
Publication date: 2026/07/25
Leppik LiudmilaWeber BirteSchindler Cora RFunda LouiseKrüger MarcusProschinger SebastianHenrich DirkMarzi Ingo